Literature DB >> 34742778

Impact of drug treatment and drug interactions in post-stroke epilepsy.

Lanqing Zhao1, Jinwei Li2, Reetta Kälviäinen3, Jukka Jolkkonen4, Chuansheng Zhao5.   

Abstract

Stroke is a huge burden on our society and this is expected to grow in the future due to the aging population and the associated co-morbidities. The improvement of acute stroke care has increased the survival rate of stroke patients, and many patients are left with permanent disability, which makes stroke the main cause of adult disability. Unfortunately, many patients face other severe complications such as post-stroke seizures and epilepsy. Acute seizures (ASS) occur within 1 week after the stroke while later occurring unprovoked seizures are diagnosed as post-stroke epilepsy (PSE). Both are associated with a poor prognosis of a functional recovery. The underlying neurobiological mechanisms are complex and poorly understood. There are no universal guidelines on the management of PSE. There is increasing evidence for several risk factors for ASS/PSE, however, the impacts of recanalization, drugs used for secondary prevention of stroke, treatment of stroke co-morbidities and antiseizure medication are currently poorly understood. This review focuses on the common medications that stroke patients are prescribed and potential drug interactions possibly complicating the management of ASS/PSE.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute seizures; Antihypertensive drugs; Antiseizure medication; Post-stroke epilepsy; Recanalization; Secondary prevention; Statins

Mesh:

Year:  2021        PMID: 34742778     DOI: 10.1016/j.pharmthera.2021.108030

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  1 in total

1.  Clinical Characteristics and Gene Mutation Analysis of Poststroke Epilepsy.

Authors:  Deju Shen; Yuqin Deng; Chunyan Lin; Jianshu Li; Xuehua Lin; Chaoning Zou
Journal:  Contrast Media Mol Imaging       Date:  2022-08-29       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.